

## PROVINCIAL FUNDING SUMMARY

### Sunitinib malate (Sutent) for Pancreatic Neuroendocrine Tumours

pERC Recommendation: Recommends with condition on the cost-effectiveness being improved to an acceptable level

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: May 18, 2012

This information is current as of April 28, 2014. The use of this document is directed by [pCODR's Terms of Use](#).

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Jun 1, 2011	Well to moderately differentiated, unresectable or metastatic pancreatic neuroendocrine tumours (PNET); ECOG performance status 0-2; adequate hematologic, hepatic and renal function; and Compassionate Access Program (CAP) approval granted by BCCA. (Note: Approvals will only be given for one of sunitinib or everolimus - not both, unless due to intolerance within the first month of therapy.)
AB	Funded	Mar 25, 2013	Unresectable locally advanced or metastatic well-differentiated pancreatic neuroendocrine tumors (pancreatic NET), whose disease is progressive and who have not previously been treated with everolimus (unless intolerant)
SK	Funded	Feb 1, 2013	Treatment of patients with progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (pNET) with good performance status (ECOG 0-2) Note: Patients whose disease progresses on Sunitinib are not eligible for SCA funded treatment with Everolimus for pNET

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
MB	Funded	Apr 16, 2014	<p>For the treatment of patients with progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (pNET) with good performance status (ECOG 0-2), until disease progression.</p> <p>Note: Patients whose disease progresses on sunitinib are not eligible for funded treatment with everolimus for pNET.</p> <p>Approval Period: 12 months</p> <p>Recommended Dose: 37.5mg daily until disease progression or development of unacceptable toxicity requiring discontinuation of sunitinib</p> <p>Renewals will be considered for patients who do not have evidence of disease progression AND who have not developed unacceptable toxicities that require discontinuation of sunitinib.</p>
ON	Funded	Sep 19, 2013	<p>For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors ("pNET") with good performance status (ECOG 0-2), until disease progression.</p> <p>Dosing: 37.5mg daily</p> <p>Approval period: 1 year</p> <p>Exclusion: Sutent will not be approved for 2nd line sequential therapy after everolimus failure in the 1st line setting.</p>
NS	Funded	Dec 1, 2013	<p>For the treatment of patients with progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (pNET) with good performance status (ECOG 0-2), until disease progression.</p>
NB	Funded	Nov 8, 2013	<p>For the treatment of patients with progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (pNET) with an ECOG performance status of 0-2, until disease progression.</p>

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
NL	Funded	Feb 24, 2014	<p>For the treatment of patients with progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (pNET) with good performance status (ECOG 0-2), until disease progression.</p> <p>Note: Patients whose disease progresses on sunitinib are not eligible for funded treatment with everolimus for pNET.</p> <p>Approval Period: 12 months</p> <p>Recommended Dose: 37.5mg daily until disease progression or development of unacceptable toxicity requiring discontinuation of sunitinib</p> <p>Renewals will be considered for patients who do not have evidence of disease progression AND who have not developed unacceptable toxicities that require discontinuation of sunitinib.</p>
PEI	Under provincial consideration*		

*\*Under provincial consideration* means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pricing Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.